Form 4: Apogee Therapeutics Director Granted Stock Options Valued at $41.66 Per Share

Apogee Therapeutics, Inc. director William A. Jones Jr. was granted stock options to purchase 14,461 shares of common stock at an exercise price of $41.66 per share, vesting one year from the grant date.

Summary

• William A. Jones Jr., a Director of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant occurred on June 17, 2025, and was reported via a Form 4 filing on June 20, 2025.
• The options allow the purchase of 14,461 shares of Apogee Therapeutics' common stock.
• The exercise price for these options is $41.66 per share.
• The options will vest on the one-year anniversary of the grant date, specifically June 17, 2026, contingent on Mr. Jones Jr.'s continued service to the company.
• The options have an expiration date of June 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns management incentives with shareholder interests, promoting long-term value creation. While it introduces potential future dilution, this is a standard and expected part of compensation.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.
• It represents a form of non-cash compensation, preserving the company's cash reserves.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity.

Risks

• The value of the options is dependent on the future market price of Apogee Therapeutics' common stock exceeding the exercise price of $41.66, posing a risk that the options may not become 'in-the-money' if the stock price declines or stagnates.
• The vesting condition requires continued service, meaning the director would forfeit unvested options if their service terminates before the vesting date.

Future Outlook

The stock options are subject to a one-year vesting period, indicating a future milestone for the director to fully realize the benefit of the grant, contingent on continued service to the company.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals (where Apogee Therapeutics operates), serving as a standard component of executive and director compensation packages aimed at aligning leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice in publicly traded companies, particularly in growth-oriented sectors like biotechnology, where equity-based incentives are prevalent.
• The vesting schedule of one year is a common period for such grants, balancing immediate incentive with long-term retention.
• The exercise price of $41.66, presumably the market price on the grant date, is typical for at-the-money option grants to ensure alignment with future stock performance.

Related Party Transactions

• The grant of stock options to William A. Jones Jr., a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term company performance.
• Employees: No direct impact mentioned, but generally, such grants are part of a broader compensation philosophy that can affect employee morale and retention.

Next Steps

• The stock options granted to William A. Jones Jr. are scheduled to vest on June 17, 2026, provided he continues his service to Apogee Therapeutics, Inc.

Key Dates

Keywords

Apogee Therapeutics, APGE, Stock Options, Form 4, SEC Filing, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, Vesting